The impact of genetic testing on physician practice in specialized cardiovascular clinics
Journal of Clinical Lipidology · 2026
DOI: 10.1016/j.jacl.2026.01.017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Lipidology, 2026. Verfasst von Arsalan Hamid und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Baylor College of Medicine, Houston, TX, USA (Drs Hamid, Nambi, Abushamat, and Ballantyne). Hauptthemen laut MEDLINE: Genetic Testing, Hyperlipoproteinemia Type II, Practice Patterns, Physicians', Cardiovascular Diseases. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, Illumina Inc.
Abstract (Originalsprache)
BACKGROUND: Although familial hypercholesterolemia (FH) is a US Centers for Disease Control and Prevention tier 1 condition for genetic testing, the impact of testing on clinical outcomes is unclear. OBJECTIVE: We aimed to assess whether genetic testing alters lipid management in HeartCare participants. METHODS: For participants with pathogenic/likely pathogenic variants for FH observed at Baylor College of Medicine cardiology clinics, data on laboratory values, medication prescriptions, and diagnoses were collected and compared before and after genetic testing. RESULTS: In the 20 participants with APOB/LDLR variants and complete data, low-density lipoprotein cholesterol (LDL-C) was numerically lower but not significantly different before vs after genetic testing (103 vs 79.5 mg/dL). Sixteen (80%) participants were from the lipid clinic; the majority had a preexisting FH diagnosis. LDL-C levels were numerically lower, and more patients received proprotein convertase subtilisin/kexin type 9 inhibitor prescriptions after genetic testing; however, the difference was not statistically significant. CONCLUSIONS: The majority of patients with FH achieved LDL-C
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Baylor College of Medicine, Houston, TX, USA (Drs Hamid, Nambi, Abushamat, and Ballantyne).
- School of Medicine, Baylor College of Medicine, Houston, TX, USA (Sewell).
- Illumina Inc, San Diego, CA, USA (Drs Bhatt and Spencer, and Hostin).
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, USA (Metcalf and Dr Gibbs).
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, USA (Metcalf and Dr Gibbs); Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA (Drs Gibbs and Ballantyne).
- Department of Medicine, Baylor College of Medicine, Houston, TX, USA (Drs Hamid, Nambi, Abushamat, and Ballantyne); Department of Medicine, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USA (Dr Nambi).
Förderung
- NIDDK NIH HHS
- Illumina Inc
Zitieren
APA
Hamid, A., Sewell, T., Bhatt, S., Spencer, S., Hostin, D., Metcalf, G. A., Gibbs, R. A., Nambi, V., Abushamat, L. A., & Ballantyne, C. M. (2026). The impact of genetic testing on physician practice in specialized cardiovascular clinics. Journal of Clinical Lipidology. https://doi.org/10.1016/j.jacl.2026.01.017
Vancouver
Hamid A, Sewell T, Bhatt S, Spencer S, Hostin D, Metcalf GA, et al. The impact of genetic testing on physician practice in specialized cardiovascular clinics. Journal of Clinical Lipidology. 2026. doi:10.1016/j.jacl.2026.01.017
BibTeX
@article{Hamid2026,
author = {Hamid, Arsalan and Sewell, Tyler and Bhatt, Sucheta and Spencer, Scott and Hostin, Damon and Metcalf, Ginger A and Gibbs, Richard A and Nambi, Vijay and Abushamat, Layla A and Ballantyne, Christie M},
title = {The impact of genetic testing on physician practice in specialized cardiovascular clinics},
journal = {Journal of Clinical Lipidology},
year = {2026},
doi = {10.1016/j.jacl.2026.01.017}
}
EUVIMED